Do you want to read an article? Please log in or register.
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
Lung Cancer
Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data
Clin Lung Cancer
Hettinger GCN, Long Q, Parikh RB
doi: 10.1016/j.cllc.2025.09.010
Lung Cancer
Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
J Clin Med
Yue H, Zhou Q, Wang S, Li S, Li J, La H, Meng S
doi: 10.3390/jcm15176749
RECOMMENDED
Lung Cancer
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A
doi: 10.1016/j.cllc.2025.12.007
Lung Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England
Lung Cancer
Karim N, Arnold K, Summers Y, Akram T, Trankov N, Vladimirova A, Chopra D, Mesa-Frias M, Waterhouse D, Stollenwerk B
doi: 10.1016/j.lungcan.2026.109469
Lung Cancer
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study
J Clin Med
Koren E, Yaacov A, Zidan J, C Roisman L, Peled N, Asna N
doi: 10.3390/jcm15124757
RECOMMENDED
Lung Cancer
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A
doi: 10.1016/j.ejca.2026.116902
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung Cancer
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L
Clin Lung Cancer
Kataoka S, Shukuya T, Ohtsu H, Miyawaki T, Fujimoto D, Hayashi H, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Otsubo K, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Yamamoto N, Okamoto I, Takahashi K
doi: 10.1016/j.cllc.2025.12.002